adrabetadex
Hearing Impairment Including Permanent Hearing Loss
LEMBAZ can cause hearing impairment. LEMBAZ-treated patients experienced permanent hearing impairment that ranged from mild to profound hearing loss, including in some patients with normal hearing at baseline. Observed hearing impairment predominantly impacted higher frequencies (at least 2,000 to 8,000 Hz) but hearing impairment at mid and lower frequencies (500 to 2,000 Hz) was also observed [see Adverse Reactions (6.1)].
Recommendations to mitigate the ototoxicity risk are as follows:
- Prior to LEMBAZ use, perform a comprehensive audiology evaluation (e.g., pure tone audiometry, speech recognition, tympanometry) to establish baseline hearing levels [see Dosage and Administration (2.1)].
- During LEMBAZ treatment, modify the LEMBAZ dosage based on comprehensive audiology evaluations as follows:
When a patient remains at the same LEMBAZ dosage level for 2 consecutive doses or has reached the maximum dosage, perform comprehensive audiology evaluations at one-month intervals until 3 consecutive, stable audiology results are obtained, and then repeat the comprehensive audiology evaluation every 12 months.
- Do not increase the dosage if hearing impairment is observed as defined in subsection 2.3 [see Dosage and Administration (2.3)].
In patients with LEMBAZ-associated hearing impairment, there are insufficient data to determine if continuing treatment at the current dosage increases the risk of further hearing impairment or if lowering the LEMBAZ dosage reduces the risk of additional hearing impairment.